Merz Aesthetics® Introduces New BELOTERO®Syringe Offering Greater Precision, Comfort and Ease of Use
Redesigned syringe seamlessly blends innovation and functionality, setting a new standard for precision and ease in the injection experience.
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®*.The new syringe is ergonomically engineered to elevate the treatment experience, offering greater precision, comfort, and ease of use. The new syringe will launch first in Europe, and then will expand to markets worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251102677784/en/
“As the first region to introduce this innovation ahead of our global expansion, I’m proud to share this exciting milestone in BELOTERO®’s history as a trusted leader in hyaluronic acid treatments,” said Gonzalo Mibelli, President EMEA region.
What is BELOTERO®?
BELOTERO® is a thoughtfully designed, comprehensive range of highly cohesive hyaluronic acid fillers, developed to deliver predictable, harmonious results through seamless tissue integration. The full portfolio offers tailored solutions to enhance facial features, improve skin quality, and visibly reduce signs of aging, all with long-lasting**, natural-looking outcomes.2-4
BELOTERO® recently marked 20 successful years in the aesthetics market, with over 18 million syringes sold worldwide, a true testament to its legacy.3
Smart Design. Precise Control. Same Trusted Formula.
“From a design perspective, the new BELOTERO® syringe* delivers both aesthetics and functionality, particularly with its advanced haptics and ergonomic finger-grip,” said Dr. Tatjana Pavicic, a board-certified dermatologist in Munich, Germany. “The anti-slip, signature color-coded silicone surfaces enhance user experience, providing easy identification, practitioner comfort, and enhanced stability during procedures.”
With a patent-protected design developed exclusively for BELOTERO®, the new syringe, with the same trusted formula, stands out in the global marketplace with several key improvements, such as:
- Ergonomic Design: The redesigned syringe offers a more comfortable grip, making handling easier during procedures.4
- Precision at Every Angle: Engineered for consistent syringe performance, the syringe adapts to various angles, providing greater control and stability.
- Improved Safety Design: An integrated Luer Lock system keeps the needle securely attached, supporting safer administration.
Clinically Validated and Recognized by Experts
“We are thrilled that our new BELOTERO® syringe* has already been recognized by a panel of expert users for providing the volume control, adaptability and consistent handling we know our customers and patients are looking for,” said Alexis Stern, Global Chief Marketing Officer at Merz Aesthetics. “In fact, 93% of users rated the new BELOTERO® syringe* as easy and intuitive.”4
The new BELOTERO® syringe will launch starting with BELOTERO® Balance®, BELOTERO® Soft , and BELOTERO® Intense in Austria, Belgium, Netherlands, Luxembourg, Germany, Italy, Switzerland, Spain, Portugal, the United Kingdom, Ireland, and Malta, followed by a phased global rollout. All BELOTERO® products with the current syringe remain available for use as indicated.
*Available for BELOTERO® Balance, Intense, and Soft
** Depending on product used, effects duration ranges from 6 months to 18 months based on clinical data.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients, and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables and devices, devices designed to meet each patient’s needs with high quality standards. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
All BELOTERO® products referred contain lidocaine, as BELOTERO® without lidocaine has been discontinued, with the exception of BELOTERO® Revive designed without lidocaine. For your information, BELOTERO® – lidocaine and non-lidocaine share the same product specifications, with the key difference being the inclusion (or absence) of lidocaine.
Important BELOTERO® Soft Lidocaine, BELOTERO® Balance Lidocaine, and BELOTERO® Intense Lidocaine Hyaluronic Acid Treatment Considerations (Regions to update based on local safety language)
BELOTERO® Soft Lidocaine is an injectable biodegradable implant intended for filling of perioral fine lines. BELOTERO® Soft Lidocaine is a device without an intended medical purpose. BELOTERO® Soft Lidocaine is indicated for injection into the superficial to mid-dermis for treatment of perioral fine lines.
BELOTERO® Balance Lidocaine is an injectable biodegradable implant intended for filling of facial wrinkles and folds as well as for lip enhancement. BELOTERO® Balance Lidocaine is a device without an intended medical purpose. BELOTERO® Balance Lidocaine is indicated for injection into the superficial to mid-dermis for treatment of naso-labial folds, marionette lines, perioral lines and oral commissures. BELOTERO® Balance Lidocaine is indicated for submucosal or subcutaneous injection for lip enhancement.
BELOTERO® Intense Lidocaine is an injectable biodegradable implant intended for filling of deep facial wrinkles and folds as well as to restore and enhance soft tissue volume. BELOTERO® Intense Lidocaine is a device without an intended medical purpose. BELOTERO® Intense Lidocaine is indicated for injection into the deep dermis for treatment of nasolabial folds and marionette lines. BELOTERO® Intense Lidocaine is indicated for submucosal or subcutaneous injection for lip enhancement.
References
- Fischer TC, et al. Facial Plast Surg. 2016 Jun;32(3):283-
- Molliard S.G., et al. J Med Behav Biomed Mater. 2016;61:290-8.
- Van Loghem, J. et al. Clin Cosm Inv Dermatol. 2021:14 1175-1
- Data on File. (CE approval).
- Data on file. 2021 Emergo Design Change Validation Report.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251102677784/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Maxion Announces Strategic Actions to Serve Growing Demand for Light Vehicle Aluminum Wheels in South America3.11.2025 23:38:00 CET | Press release
Includes Joint Venture through Polimetal to Increase Capacity in Argentina Iochpe-Maxion (B3: MYPK3) through its wheels business, Maxion Wheels, announced the strategic expansion of its light vehicle aluminum wheels business in South America with the redeployment of existing global assets to Brazil, and the acquisition of a 50.1% shareholding in Polimetal, a leading producer of aluminum wheels in Argentina. “Passenger car sales continue to rise across South America, with our wheels business, especially light vehicle aluminum wheels, continuing to gain share in Mercosur,” stated Pieter Klinkers, President and CEO of Iochpe-Maxion. “To address this growing market and corresponding aluminum wheel demand, Maxion Wheels is implementing three strategic initiatives. First is the utilization of our global operations, together with our domestic forces in Brazil, to support the immediate additional demand. Second is the redeployment of existing global assets to our two Brazilian light vehicle al
GigaDevice Highlights Breakthroughs Across AI, Power, and Consumer Applications at Embedded World 20253.11.2025 17:00:00 CET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, will present its latest breakthroughs in AI-driven facial and voice recognition, power management, and consumer applications, at this year’s Embedded World North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103394601/en/ This is the second running of EWNA, with the expo taking place in Anaheim, CA, from the 4th of November. GigaDevice’s technology will be on display at Booth #6085 throughout the three-day exhibition. Like its European sister show, the event brings together many of the leading developers and system architects from across the embedded electronics sector. GigaDevice's demonstrations will highlight the performance and versatility of its GD32 MCU family across several demanding applications: Edge AI Recognition Systems: GigaDevice will showcase facial and voice reco
Coulson Aviation Develops SafeFuel, the First Onboard Fuel Quality Assurance and Protection System3.11.2025 16:30:00 CET | Press release
Coulson Aviation (USA), the world’s largest aerial firefighting company and operator of the most advanced mixed fixed- and rotary-wing firefighting fleet, has developed SafeFuel, the aviation industry’s first onboard system designed to verify fuel quality and detect contamination during refueling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103342390/en/ Coulson SafeFuel is the world’s first patented onboard fuel-quality assurance and protection system. It continuously analyzes the product during refueling, detecting contamination or chemical degradation in real-time, preventing unsafe fuel from ever reaching the tanks. The innovation comes amid growing safety concerns following multiple fuel-related incidents in military and commercial aviation, and recent Navy aircraft accidents under investigation. Coulson Aviation’s aircraft often operate in remote environments around the world, where the risk of contaminated or of
Stefanini Group and Scopism Survey Reveals Rapid AI Adoption, Identifies Key Global Trends Shaping Service Integration and Management (SIAM)3.11.2025 15:42:00 CET | Press release
Launched today at the Scopism Service North Conference in Manchester, UK, the report finds that 85% of organizations now use AI in key SIAM processes, while also highlighting integration and data privacy roadblocks Stefanini Group, a global tech consulting company with strong expertise in digital transformation and artificial intelligence solutions, and Scopism, a global leader in Service Integration and Management (SIAM) best practices, today announced the release of the Global SIAM Survey 2025 White Paper. The eighth annual report, sponsored by Stefanini, was launched and presented by a panel at the Scopism Service North Conference in Manchester, UK, and provides unrivalled insights into SIAM adoption, maturity, and emerging trends worldwide. The survey continues to track the impact of artificial intelligence (AI) on SIAM models. Results show that while reported use of AI in SIAM models overall has remained stable, AI adoption within specific areas, such as incident management, has i
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting3.11.2025 15:31:00 CET | Press release
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on Sunday, December 7, 2025, from 11:00 a.m.-12:30 p.m. ET Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual Meeting, to be held December 6 – 9, 2025, in Orlando. "Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom